Article info
PDFClinical and epidemiological research
Extended report
Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study
- Correspondence to Dr Paul P Tak, GlaxoSmithKline Research and Development, Stevenage SG1 2NY, UK; Paul-peter.x.tak{at}gsk.com
Citation
Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study
Publication history
- Received February 17, 2017
- Revised July 11, 2017
- Accepted July 18, 2017
- First published August 30, 2017.
Online issue publication
October 31, 2019
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/